Vicore Pharma Holding
Develops ATRAG drugs and digital therapeutics for respiratory diseases.
VICO | ST
Overview
Corporate Details
- ISIN(s):
- SE0007577895 (+1 more)
- LEI:
- 549300KTNBPTZLF01130
- Country:
- Sweden
- Address:
- Postbox 14, 414 51 Göteborg
- Website:
- https://vicorepharma.com/
- Sector:
- Manufacturing
Description
Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), with disease-modifying potential. The company's research focuses on diseases where the AT2 receptor has a central role in stopping and reversing pathology. Its lead candidate, buloxibutid (C21), is a first-in-class, orally available small molecule ATRAG in clinical development for idiopathic pulmonary fibrosis (IPF). Vicore is also developing Almee™, a digital therapeutic based on cognitive behavioral therapy for the psychological impact of pulmonary fibrosis, which has received FDA Breakthrough Device Designation. The company utilizes its expertise in ATRAG chemistry and biology to build a pipeline primarily focused on respiratory diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-28 09:00 |
Increase in number of shares and votes in Vicore Pharma
|
English | 107.0 KB | ||
| 2025-11-28 09:00 |
Ökning av antalet aktier och röster i Vicore Pharma
|
Swedish | 107.5 KB | ||
| 2025-11-27 10:04 | Swedish | 10.7 KB | |||
| 2025-11-14 11:50 | Swedish | 10.4 KB | |||
| 2025-11-13 01:50 |
Vicore Pharma har framgångsrikt genomfört en riktad nyemission om cirka 48 milj…
|
Swedish | 127.3 KB | ||
| 2025-11-13 01:50 |
Vicore Pharma announces successful execution of a directed share issue of appro…
|
English | 125.9 KB | ||
| 2025-11-12 17:31 |
Vicore Pharma avser att genomföra en riktad nyemission av aktier
|
Swedish | 122.4 KB | ||
| 2025-11-12 17:31 |
Vicore Pharma intends to carry out a directed share issue
|
English | 120.9 KB | ||
| 2025-11-05 08:00 | Swedish | 2.2 MB | |||
| 2025-11-05 08:00 | English | 2.2 MB | |||
| 2025-11-03 09:00 |
Vicore announces the Nomination Committee for the 2026 Annual General Meeting
|
English | 104.6 KB | ||
| 2025-11-03 09:00 |
Vicore offentliggör valberedningen inför årsstämman 2026
|
Swedish | 108.2 KB | ||
| 2025-08-22 08:00 | Swedish | 2.2 MB | |||
| 2025-08-22 08:00 | English | 2.2 MB | |||
| 2025-06-30 09:00 |
Increase in number of shares and votes in Vicore Pharma
|
English | 102.5 KB |
Automate Your Workflow. Get a real-time feed of all Vicore Pharma Holding filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Vicore Pharma Holding
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Vicore Pharma Holding via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-13 | Ahmed Mousa | Other | Buy | 11,034 | 90,920.16 SEK |
| 2025-05-13 | Ahmed Mousa | Other | Buy | 757 | 6,230.11 SEK |
| 2024-10-24 | Johannes Schikan | Other | Other | 355 | 2,485.00 SEK |
| 2024-09-23 | Ann Barbier | Other | Buy | 42,500 | 298,775.00 SEK |
| 2024-09-11 | Ahmed Mousa | Other | Buy | 32,000 | 248,169.60 SEK |
| 2024-09-10 | Ahmed Mousa | Other | Buy | 95,000 | 752,248.00 SEK |
| 2022-06-08 | Jacob Uno Stanley Gunterberg | Other | Buy | 6,400 | 220,800.00 SEK |
| 2022-06-03 | Johannes Schikan | Other | Buy | 4,000 | 119,880.00 SEK |
| 2022-06-03 | Sara Malcus | Other | Buy | 2,902 | 87,495.30 SEK |
| 2022-06-01 | Maarten Kraan | Other | Buy | 4,025 | 121,152.50 SEK |
Peer Companies
